Fonar (FONR) Competitors

$18.90 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$18.90 0.00 (-0.03%)

As of 05/22/2026 06:01 PM Eastern

FONR vs. KIDS, BBNX, DCTH, CLPT, and CV

Should you buy Fonar stock or one of its competitors? MarketBeat compares Fonar with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Fonar include OrthoPediatrics (KIDS), Beta Bionics (BBNX), Delcath Systems (DCTH), ClearPoint Neuro (CLPT), and CapsoVision (CV). These companies are all part of the "medical equipment" industry.

How does Fonar compare to OrthoPediatrics?

Fonar (NASDAQ:FONR) and OrthoPediatrics (NASDAQ:KIDS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, risk and profitability.

50.6% of Fonar shares are held by institutional investors. Comparatively, 69.1% of OrthoPediatrics shares are held by institutional investors. 7.9% of Fonar shares are held by company insiders. Comparatively, 32.7% of OrthoPediatrics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

OrthoPediatrics has a consensus target price of $24.44, suggesting a potential upside of 33.07%. Given OrthoPediatrics' stronger consensus rating and higher probable upside, analysts plainly believe OrthoPediatrics is more favorable than Fonar.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fonar	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
OrthoPediatrics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

Fonar has higher earnings, but lower revenue than OrthoPediatrics. OrthoPediatrics is trading at a lower price-to-earnings ratio than Fonar, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fonar	$104.35M	1.12	$8.33M	$1.00	18.90
OrthoPediatrics	$236.35M	2.00	-$39.65M	-$1.68	N/A

Fonar has a net margin of 6.35% compared to OrthoPediatrics' net margin of -16.31%. Fonar's return on equity of 4.12% beat OrthoPediatrics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fonar	6.35%	4.12%	3.07%
OrthoPediatrics	-16.31%	-7.01%	-4.86%

Fonar has a beta of 0.96, meaning that its share price is 4% less volatile than the broader market. Comparatively, OrthoPediatrics has a beta of 0.99, meaning that its share price is 1% less volatile than the broader market.

In the previous week, Fonar and Fonar both had 1 articles in the media. OrthoPediatrics' average media sentiment score of 1.17 beat Fonar's score of 0.15 indicating that OrthoPediatrics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fonar	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
OrthoPediatrics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

OrthoPediatrics beats Fonar on 10 of the 16 factors compared between the two stocks.

How does Fonar compare to Beta Bionics?

Beta Bionics (NASDAQ:BBNX) and Fonar (NASDAQ:FONR) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk, media sentiment and valuation.

Fonar has higher revenue and earnings than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than Fonar, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beta Bionics	$100.25M	5.25	-$73.20M	-$1.51	N/A
Fonar	$104.35M	1.12	$8.33M	$1.00	18.90

Fonar has a net margin of 6.35% compared to Beta Bionics' net margin of -60.27%. Fonar's return on equity of 4.12% beat Beta Bionics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beta Bionics	-60.27%	-23.00%	-20.55%
Fonar	6.35%	4.12%	3.07%

50.6% of Fonar shares are held by institutional investors. 5.3% of Beta Bionics shares are held by company insiders. Comparatively, 7.9% of Fonar shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Beta Bionics has a beta of 3.29, suggesting that its stock price is 229% more volatile than the broader market. Comparatively, Fonar has a beta of 0.96, suggesting that its stock price is 4% less volatile than the broader market.

Beta Bionics currently has a consensus price target of $20.00, indicating a potential upside of 69.20%. Given Beta Bionics' stronger consensus rating and higher possible upside, research analysts plainly believe Beta Bionics is more favorable than Fonar.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beta Bionics	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.67
Fonar	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Beta Bionics had 3 more articles in the media than Fonar. MarketBeat recorded 4 mentions for Beta Bionics and 1 mentions for Fonar. Fonar's average media sentiment score of 0.15 beat Beta Bionics' score of -0.22 indicating that Fonar is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beta Bionics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Fonar	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Fonar beats Beta Bionics on 10 of the 17 factors compared between the two stocks.

How does Fonar compare to Delcath Systems?

Fonar (NASDAQ:FONR) and Delcath Systems (NASDAQ:DCTH) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability, media sentiment and analyst recommendations.

Fonar has a net margin of 6.35% compared to Delcath Systems' net margin of 0.62%. Fonar's return on equity of 4.12% beat Delcath Systems' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fonar	6.35%	4.12%	3.07%
Delcath Systems	0.62%	0.51%	0.46%

Delcath Systems has a consensus price target of $22.50, suggesting a potential upside of 104.17%. Given Delcath Systems' stronger consensus rating and higher possible upside, analysts plainly believe Delcath Systems is more favorable than Fonar.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fonar	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Delcath Systems	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43

Fonar has higher revenue and earnings than Delcath Systems. Fonar is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fonar	$104.35M	1.12	$8.33M	$1.00	18.90
Delcath Systems	$85.23M	4.46	$2.70M	$0.01	1,102.00

In the previous week, Delcath Systems had 2 more articles in the media than Fonar. MarketBeat recorded 3 mentions for Delcath Systems and 1 mentions for Fonar. Delcath Systems' average media sentiment score of 0.27 beat Fonar's score of 0.15 indicating that Delcath Systems is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fonar	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Delcath Systems	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Fonar has a beta of 0.96, suggesting that its share price is 4% less volatile than the broader market. Comparatively, Delcath Systems has a beta of 0.54, suggesting that its share price is 46% less volatile than the broader market.

50.6% of Fonar shares are owned by institutional investors. Comparatively, 61.1% of Delcath Systems shares are owned by institutional investors. 7.9% of Fonar shares are owned by company insiders. Comparatively, 19.4% of Delcath Systems shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Delcath Systems beats Fonar on 9 of the 16 factors compared between the two stocks.

How does Fonar compare to ClearPoint Neuro?

Fonar (NASDAQ:FONR) and ClearPoint Neuro (NASDAQ:CLPT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, institutional ownership, media sentiment, earnings, valuation, dividends and analyst recommendations.

In the previous week, ClearPoint Neuro had 3 more articles in the media than Fonar. MarketBeat recorded 4 mentions for ClearPoint Neuro and 1 mentions for Fonar. Fonar's average media sentiment score of 0.15 beat ClearPoint Neuro's score of 0.15 indicating that Fonar is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fonar	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ClearPoint Neuro	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ClearPoint Neuro has a consensus price target of $18.00, suggesting a potential upside of 57.34%. Given ClearPoint Neuro's stronger consensus rating and higher probable upside, analysts plainly believe ClearPoint Neuro is more favorable than Fonar.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fonar	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
ClearPoint Neuro	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

50.6% of Fonar shares are held by institutional investors. Comparatively, 30.1% of ClearPoint Neuro shares are held by institutional investors. 7.9% of Fonar shares are held by company insiders. Comparatively, 6.9% of ClearPoint Neuro shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Fonar has a beta of 0.96, suggesting that its share price is 4% less volatile than the broader market. Comparatively, ClearPoint Neuro has a beta of 1.29, suggesting that its share price is 29% more volatile than the broader market.

Fonar has a net margin of 6.35% compared to ClearPoint Neuro's net margin of -71.57%. Fonar's return on equity of 4.12% beat ClearPoint Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fonar	6.35%	4.12%	3.07%
ClearPoint Neuro	-71.57%	-140.96%	-36.98%

Fonar has higher revenue and earnings than ClearPoint Neuro. ClearPoint Neuro is trading at a lower price-to-earnings ratio than Fonar, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fonar	$104.35M	1.12	$8.33M	$1.00	18.90
ClearPoint Neuro	$36.97M	9.28	-$25.54M	-$1.01	N/A

Summary

Fonar beats ClearPoint Neuro on 10 of the 16 factors compared between the two stocks.

How does Fonar compare to CapsoVision?

Fonar (NASDAQ:FONR) and CapsoVision (NASDAQ:CV) are both small-cap medical equipment companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, profitability, valuation, institutional ownership, analyst recommendations, earnings, risk and dividends.

Fonar has a net margin of 6.35% compared to CapsoVision's net margin of -198.87%. Fonar's return on equity of 4.12% beat CapsoVision's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fonar	6.35%	4.12%	3.07%
CapsoVision	-198.87%	N/A	-136.03%

50.6% of Fonar shares are owned by institutional investors. 7.9% of Fonar shares are owned by insiders. Comparatively, 2.3% of CapsoVision shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Fonar has higher revenue and earnings than CapsoVision. CapsoVision is trading at a lower price-to-earnings ratio than Fonar, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fonar	$104.35M	1.12	$8.33M	$1.00	18.90
CapsoVision	$13.55M	24.48	-$25.32M	-$2.34	N/A

In the previous week, Fonar and Fonar both had 1 articles in the media. Fonar's average media sentiment score of 0.15 beat CapsoVision's score of 0.00 indicating that Fonar is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fonar	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CapsoVision	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

CapsoVision has a consensus price target of $8.50, suggesting a potential upside of 28.01%. Given CapsoVision's stronger consensus rating and higher possible upside, analysts clearly believe CapsoVision is more favorable than Fonar.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fonar	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
CapsoVision	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Summary

Fonar beats CapsoVision on 10 of the 15 factors compared between the two stocks.

Get Fonar News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FONR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FONR vs. The Competition

Export

Metric	Fonar	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$116.64M	$8.52B	$6.46B	$12.34B
Dividend Yield	N/A	2.50%	2.76%	5.28%
P/E Ratio	18.90	16.24	21.22	25.66
Price / Sales	1.12	8.28	562.28	86.31
Price / Cash	8.99	17.11	43.49	56.67
Price / Book	0.71	4.06	10.31	7.14
Net Income	$8.33M	$224.05M	$3.57B	$335.98M
7 Day Performance	0.19%	5.34%	6.43%	4.15%
1 Month Performance	0.37%	-0.08%	3.57%	2.54%
1 Year Performance	33.76%	0.98%	34.07%	35.06%

Fonar Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FONR Fonar	1.4668 of 5 stars	$18.90 flat	N/A	+33.8%	$116.64M	$104.35M	18.90	480
KIDS OrthoPediatrics	3.6759 of 5 stars	$18.23 +0.5%	$24.44 +34.1%	-11.8%	$465.93M	$236.35M	N/A	200	Positive News
BBNX Beta Bionics	3.046 of 5 stars	$9.40 flat	$20.00 +112.8%	-18.1%	$418.88M	$100.25M	N/A	294
DCTH Delcath Systems	2.1638 of 5 stars	$10.85 -2.2%	$22.50 +107.4%	-31.6%	$382.85M	$85.23M	1,085.00	60	Gap Up
CLPT ClearPoint Neuro	2.2165 of 5 stars	$11.17 +0.4%	$18.00 +61.1%	-3.8%	$333.78M	$36.97M	N/A	110

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FONR) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Fonar (FONR) Competitors

FONR vs. KIDS, BBNX, DCTH, CLPT, and CV

How does Fonar compare to OrthoPediatrics?

Summary

How does Fonar compare to Beta Bionics?

Summary

How does Fonar compare to Delcath Systems?

Summary

How does Fonar compare to ClearPoint Neuro?

Summary

How does Fonar compare to CapsoVision?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FONR vs. The Competition

Fonar Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Fonar (FONR) Competitors

FONR vs. KIDS, BBNX, DCTH, CLPT, and CV

How does Fonar compare to OrthoPediatrics?

Do institutionals and insiders have more ownership in FONR or KIDS?

Do analysts recommend FONR or KIDS?

Which has stronger valuation and earnings, FONR or KIDS?

Is FONR or KIDS more profitable?

Which has more volatility & risk, FONR or KIDS?

Does the media favor FONR or KIDS?

Summary

How does Fonar compare to Beta Bionics?

Which has preferable valuation & earnings, BBNX or FONR?

Is BBNX or FONR more profitable?

Do insiders and institutionals hold more shares of BBNX or FONR?

Which has more risk and volatility, BBNX or FONR?

Do analysts recommend BBNX or FONR?

Does the media prefer BBNX or FONR?

Summary

How does Fonar compare to Delcath Systems?

Is FONR or DCTH more profitable?

Do analysts recommend FONR or DCTH?

Which has better valuation & earnings, FONR or DCTH?

Does the media prefer FONR or DCTH?

Which has more volatility & risk, FONR or DCTH?

Do insiders & institutionals have more ownership in FONR or DCTH?

Summary

How does Fonar compare to ClearPoint Neuro?

Does the media favor FONR or CLPT?

Do analysts rate FONR or CLPT?

Do insiders and institutionals have more ownership in FONR or CLPT?

Which has more risk & volatility, FONR or CLPT?

Is FONR or CLPT more profitable?

Which has preferable valuation & earnings, FONR or CLPT?

Summary

How does Fonar compare to CapsoVision?

Is FONR or CV more profitable?

Do insiders & institutionals believe in FONR or CV?

Which has stronger valuation and earnings, FONR or CV?

Does the media favor FONR or CV?

Do analysts rate FONR or CV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FONR vs. The Competition

Fonar Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools